B7H3 CAR-T cells with the TMIGD2 co-stimulatory domain exhibited superior anti-tumor activity, enhanced expansion, and improved persistence compared to traditional CAR-T cells incorporating CD28 and/or 4-1BB co-stimulatory domains. This evidence concerns the gene CD28 and neoplasm.